The high court is considering whether to roll back access to mifepristone, a key abortion medication that is part of a two-drug regimen and used in more than 60 percent of U.S. abortions.
The Alliance for Hippocratic Medicine, a coalition of antiabortion doctors and others, is arguing that the Food and Drug Administration didn't sufficiently consider safety concerns when it approved the drug in 2000 or when it removed some restrictions in 2016 and in 2021. The Justice Department, on behalf of the Biden administration, argues that the plaintiffs don't have standing in the case because they have never prescribed the drug. Danco Laboratories, the drug's manufacturer, also contends that a ruling in favor of the plaintiffs would have a chilling effect on the pharmaceutical industry.
Here are five key exchanges from Tuesday's oral arguments…
No comments:
Post a Comment